126 related articles for article (PubMed ID: 38470545)
1. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Magbanua MJM; Ahmed Z; Sayaman RW; Brown Swigart L; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Perlmutter J; Pohlmann P; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
Clin Cancer Res; 2024 Jun; 30(11):2444-2451. PubMed ID: 38470545
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM; Brown Swigart L; Ahmed Z; Sayaman RW; Renner D; Kalashnikova E; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Asare S; Liu MC; Albain K; Chien AJ; Forero-Torres A; Isaacs C; Nanda R; Tripathy D; Rodriguez A; Sethi H; Aleshin A; Rabinowitz M; Perlmutter J; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
Cancer Cell; 2023 Jun; 41(6):1091-1102.e4. PubMed ID: 37146605
[TBL] [Abstract][Full Text] [Related]
3. Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.
Giro C; Yamada AMTD; Cruz FJSM; do R Barros LA; da C A Alves B; Fonseca FLA; Del Giglio A
Breast Cancer Res Treat; 2024 Jul; 206(2):329-335. PubMed ID: 38743176
[TBL] [Abstract][Full Text] [Related]
4. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
[TBL] [Abstract][Full Text] [Related]
5. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Parsons HA; Blewett T; Chu X; Sridhar S; Santos K; Xiong K; Abramson VG; Patel A; Cheng J; Brufsky A; Rhoades J; Force J; Liu R; Traina TA; Carey LA; Rimawi MF; Miller KD; Stearns V; Specht J; Falkson C; Burstein HJ; Wolff AC; Winer EP; Tayob N; Krop IE; Makrigiorgos GM; Golub TR; Mayer EL; Adalsteinsson VA
Ann Oncol; 2023 Oct; 34(10):899-906. PubMed ID: 37597579
[TBL] [Abstract][Full Text] [Related]
7. Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy.
Elder EA; Livasy CA; Donahue EE; Neelands B; Patrick A; Needham M; Sarantou T; Hadzikadic-Gusic L; Heeke AL; White RL
Ann Surg Oncol; 2022 Dec; 29(13):8060-8069. PubMed ID: 35980548
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
[TBL] [Abstract][Full Text] [Related]
9. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
Gwark S; Kim J; Kwon NJ; Kim KY; Kim Y; Lee CH; Kim YH; Kim MS; Hong SW; Choi MY; Jeon BH; Chang S; Yu J; Park JY; Lee HJ; Lee SB; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn JH; Jung KH; Kim SB; Gong GY; Ahn SH
Sci Rep; 2020 Oct; 10(1):17466. PubMed ID: 33060768
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
Hamy AS; Darrigues L; Laas E; De Croze D; Topciu L; Lam GT; Evrevin C; Rozette S; Laot L; Lerebours F; Pierga JY; Osdoit M; Faron M; Feron JG; Laé M; Reyal F
PLoS One; 2020; 15(6):e0234191. PubMed ID: 32579551
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
Leon-Ferre RA; Whitaker KR; Suman VJ; Hoskin T; Giridhar KV; Moore RM; Al-Jarrad A; McLaughlin SA; Northfelt DW; Hunt KN; Conners AL; Moyer A; Carter JM; Kalari K; Weinshilboum R; Wang L; Ingle JN; Knutson KL; Ansell SM; Boughey JC; Goetz MP; Villasboas JC
Breast Cancer Res; 2024 Jun; 26(1):97. PubMed ID: 38858721
[TBL] [Abstract][Full Text] [Related]
14. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
16. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
17. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
[TBL] [Abstract][Full Text] [Related]
18. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
Cavallone L; Aguilar-Mahecha A; Lafleur J; Brousse S; Aldamry M; Roseshter T; Lan C; Alirezaie N; Bareke E; Majewski J; Ferrario C; Hassan S; Discepola F; Seguin C; Mihalcioiu C; Marcus EA; Robidoux A; Roy JA; Pelmus M; Basik M
Sci Rep; 2020 Sep; 10(1):14704. PubMed ID: 32895401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
